Patient-Focused Treatment Decisions in the Management of HIV: Individualizing ART Decision Making for Improved Clinical and Economic Outcomes

A continuing medical education activity provided by NAMCP and AAMCN

This activity is an archive from the live session from the 2022 Spring Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from July 1, 2022, to August 1, 2023

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by an educational grant from
ViiV Healthcare

The human immunodeficiency virus (HIV) is a lentivirus that causes HIV infection and over time acquired
immunodeficiency syndrome (AIDS). AIDS is a condition in humans in which progressive failure of the immune system allows life-threatening opportunistic infections and cancers to thrive. HIV infects vital cells in the human immune system such as helper T cells, macrophages, and dendritic cells. HIV infection leads to low levels of CD4+T cells through a number of specific mechanisms. When CD4+ T cell numbers decline below a critical level, cell mediated immunity is lost, and the body becomes progressively more susceptible to opportunistic infections. The CDC estimates that 1,218,400 persons in the United States aged 13 years and older are living with HIV infection. Additionally, an estimated 6,955 people died from HIV and AIDS in 2018. Fortunately for patients with HIV, several new therapies have become available over the past few years, and more are set to become available soon. This activity is designed to address the challenge of individualizing HIV care with current treatment guidelines and recent clinical data, emerging therapy options and combinations, strategies for newly diagnosed patients and strategies for switching therapy for virally-suppressed patients, identifying patients who would benefit from treatment alteration, the role of newer combination regimens, cost optimization for HIV therapies, emerging therapies for heavily treatment-experienced adults, patient adherence strategies, and then explain how to apply them to the optimal care of a wide variety of HIV patients.

Upon completion of this activity, participants will be able to:

  • Assess the clinical and economic burden of HIV, including factors that contribute to poor prognosis and increased costs

  • Explore optimal ART regimens based on patient- or drug-related factors, including age, comorbidities, concomitant medications, potential for ART-related toxicities, adherence, or patient preferences

  • Discuss newer therapies for heavily treatment-experienced (HTE) adults with multidrug-resistant HIV-1 infection

  • Examine the emerging role of long-acting injectable therapy for people living with HIV

  • Summarize the potential benefits and limitations of daily vs long-acting therapy in the long-term management of HIV

  • Examine the managed care considerations of new and emerging therapies, including combination options and long-acting ART, by exploring where these agents fit in the HIV management paradigm


Faculty: Timothy J. Wilkin MD, MPH
Professor of Medicine
Weill Cornell Medical College


(Relevant Financial Relationships with Ineligible Companies in the Last 24 Months):
Dr. Wilkin has served as an ad hoc consultant for Merck. Dr. Wilkin has also received funds paid to Weill Cornell from GlaxoSmithKline/Viiv. His presentation has been reviewed for any bias.
Planning Committee: Bill Williams, MD has no relevant financial relationships with an ineligible company in the last 24 months to disclose.

Jeremy Williams has no relevant financial relationships with an ineligible company in the last 24 months to disclose.

Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships with an ineligible company in the last 24 months to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This activity is supported by an educational grant from
ViiV Healthcare

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue